News
MEDICA Trade Fair 2024
Join ViennaLab at MEDICA 2024!
From November 11 - 14, 2024, meet us at the Medica Fair 2024 in Düsseldorf.
Together with BioVendor, we’ll be exhibiting exciting innovations in in-vitro diagnostics. Visit us in Hall 3, Booth A92.
Don´t miss the chance to learn more about the latest advances in in-vitro diagnostics!
2024 ESHG Conference in Berlin
ViennaLab is thrilled to announce our participation in the European Human Genetics Conference 2024 in Berlin!
Date: 1 - 4 June 2024
Location: CityCube Berlin, Germany
Stand: #420
Join us as we exhibit alongside our colleagues from BioVendor MDx.
This is a fantastic opportunity to meet the ViennaLab team and explore our cutting-edge diagnostic tools for molecular diagnostics.
oncNGS Consortium visits ViennaLab
We were honored to host the esteemed monitoring team of the oncNGS consortium (Alleanza Contro il Cancro,Institut Curie,Charité - Universitätsmedizin Berlin, and Institut Jules Bordet) at our facilities in Vienna. The discussions were incredibly productive full of innovative ideas that will shape the future of diagnostics.
It's inspiring to see how this collaboration among European institutions contribute to groundbreaking advancements in diagnostic technologies. Together, we're driving forward the development of cutting-edge innovations that will ultimately improve patient care and outcomes worldwide. For more information follow this link.
Stay tuned for more updates as we continue to push the boundaries of diagnostic excellence!
Medlab Middle East 2024
ViennaLab exhibits at Medlab Middle East 2024!
The event will be held from February 5 - 8, 2024.
ViennaLab is exhibiting together with our long-term partners, HVD VertriebsGmbH at booth Z5.C20 and our mother company, BioVendor Group at booth Z5.E29.
We look forward to meet you in person!
Holiday Season Greetings 2023
Thank you!
This year is coming to an end and we would like to use this opportunity to thank our business partners, customers, and distribution partners for your trust in us.
We wish you and your loved ones happy holidays and a prosperous New Year 2024!
ViennaLab Team
MEDICA Trade Fair 2023
Visit us at MEDICA 2023
The live event will be held from November 13 - 16, 2023 and we will be there.
We are exhibiting together with our mother company, BioVendor, in Hall 3 A92.
We are really looking forward to meet with you again in person!
NGS Contract Award Phase 2
ViennaLab Diagnostics and its partners secured funding for phase 2 of the prestigious oncNGS project.
ViennaLab Diagnostics partnered together with Euformatics and Oncompass Medicine and progressed to the phase 2 to design a state-of-the-art solution which aims to revolutionize the field of liquid biopsy and cancer detection.
Phase 2 will last 12 months, during which, we will apply our expertise to develop a non-invasive Pan-cancer cfDNA test to profile the tumor landscape and predict the best personalized treatment for every patient.
For more information, follow the link to Media Centre announcement. Please click here for the official Press Release.
EU IVDR 2017/746
IVDR promotes high levels of safety and quality while supporting innovation - focus on patient safety.
Due to our early activities in order to get IVDR compliant, we and service laboratories, who are using our products to diagnose patients, play a part in contributing to no shortages in in vitro diagnostic products and therefore patient care is secured.
We submitted the technical documentation of the first tranche of our RealFast Assays and StripAssays to the Notified Body TÜV Süd and successfully received IVD CE0123 approval.
This means, that we now offer you the following products designed and developed under IVDR and this list is steadily growing:
- alpha-Globin StripAssay [REF 4-160]
- CAH StripAssay [REF 4-380]
- CF StripAssays [REF 4-410, 4-420, 4-430, 4-440]
- FMF StripAssay [4-230]
- FMF-SAA1 StripAssay [REF 4-390]
- HLA-B27 RealFast Assay [REF 7-620/7-623]
By implementing ViennaLab assays in your diagnostic laboratory you do not have to invest time into creating technical documentation, demonstrating scientific validity, generating analytical and clinical data, performance data, etc. as these are time- and cost-intensive tasks and are all covered by ViennaLab as an IVD manufacturer, which is confirmed by the certificate issued by the Notified Body TÜV Süd. View this link here.
So, having selected ViennaLab as your supplier of diagnostic products, lie back and relax.
New family member
Think big with a smaller kit configuration
Are you planning a new microbiome project? You do not have many samples to work on at the beginning?
ViennaLab has a perfect solution for you. We now offer a smaller kit configuration – 16 reactions. This attractive set-up is intended to provide an economical solution for new users to familiarize themselves with the assay and for labs with a low sample throughput.
The new configuration is already on stock!
Follow this link to view more details.
ESHG 2023 Conference
56th European Society of Human Genetics Conference is taking place in Glasgow/UK
The live event will be held from June 10 - 13, 2023.
Scottish Event Campus / United Kingdom
ViennaLab is exhibiting together with our mother company, BioVendor, at booth #410.
We are looking forward to your visit!
Frühjahrstagung 2023
Österreichische Gesellschaft für Klinische Pathologie und Molekularpathologie / Österreichische Abteilung der Internationalen Akademie für Pathologie (ÖGPath/IAP Austria)
Die Frühjahrstagung findet vom 24. bis 25. März 2023 statt.
TechGate Vienna, Donau City Wien
ViennaLab wird abermals vom österreichischen Vertriebspartner HVD Life Science Vertriebs GmbH bei der Industrieausstellung vertreten.
Wir freuen uns auf Ihren Besuch auf unserem Messestand!
NGS Contract Award
ViennaLab Diagnostics is part of the HUFIAT Consortium awarded a contract for Phase 1 to develop an end-to-end NGS solution in the field of liquid biopsy (cfDNA).
ViennaLab Diagnostics will apply their expertise in cfDNA and genetic tests and join forces with bioinformatics experts – Euformatics and AI specialists – Oncompass Medicine to work on a solution which aims to improve the field of liquid biopsy and cancer detection.
With this non-invasive approach we will develop a Pan-cancer cfDNA test to profile the tumor landscape which will allow to predict the best personalized treatment for every patient.
Follow the link to get more information on OncNGS . Please click here for the official Press Release.